Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Trends in Antimicrobial Consumption in Tertiary Care Hospitals in Costa Rica from 2017 to 2021: A Comparative Analysis of Defined Daily Doses per 100 Bed Days and per 100 Discharges

Version 1 : Received: 4 September 2024 / Approved: 4 September 2024 / Online: 4 September 2024 (14:57:18 CEST)

How to cite: Fernandez-Barrantes, C.; Ramos-Esquivel, A.; Hernández-Soto, L. E.; Ramírez-Cardoce, M.; Garro-Zamora, L. D.; Cordero, J. C.; Grau, S. Trends in Antimicrobial Consumption in Tertiary Care Hospitals in Costa Rica from 2017 to 2021: A Comparative Analysis of Defined Daily Doses per 100 Bed Days and per 100 Discharges. Preprints 2024, 2024090365. https://doi.org/10.20944/preprints202409.0365.v1 Fernandez-Barrantes, C.; Ramos-Esquivel, A.; Hernández-Soto, L. E.; Ramírez-Cardoce, M.; Garro-Zamora, L. D.; Cordero, J. C.; Grau, S. Trends in Antimicrobial Consumption in Tertiary Care Hospitals in Costa Rica from 2017 to 2021: A Comparative Analysis of Defined Daily Doses per 100 Bed Days and per 100 Discharges. Preprints 2024, 2024090365. https://doi.org/10.20944/preprints202409.0365.v1

Abstract

Background: Antimicrobial consumption data in Latin America is scarce and usually spread out within different sources for AMC calculations, making it difficult to both standardize and compare regions through similar time frames. The main objective was to analyze antimicrobial consumption trends in Social Security tertiary care hospitals in Costa Rica in the period spanning January 2017 to December 2021, using both defined daily doses (DDD)/100 bed days and DDD/100 discharges. Methods: Retrospective observational study of antimicrobial consumption. Global consumption trends were calculated and expressed in DDD/100 bed days and DDD/100 discharges. Trends in antimicrobial consumption were analyzed using a simple linear regression model to determine potential differences in antimicrobial usage throughout the study’s duration. Results: A statistically significant increase in the consumption expressed in DDD/100 discharges was observed in the following groups: carbapenems: 35.62% (p<0.0001), trimethoprim-sulfamethoxazole: 62.50% (p<0.0001), echinocandins: 20.73% (p=0.01) and azole antifungals: 61.58% (p<0.0001). Additionally, a statistically significant increase of 40.43% in the consumption of azole antifungals expressed in DDD/100 bed days was observed (p=0.0008). In contrast, a statistically significant decrease in consumption expressed in DDD/100 discharges was identified for cephalosporins -21.97% (p<0.0001) and macrolides -51.67% (p<0.0001). Conclusions: This five-year analysis demonstrated trends over time in overall antimicrobial consumption measured in DDD/100 bed days do not correlate with trends in DDD/100 discharge rates. Continually, the comparison between DDD/100 bed days and DDD/100 discharges allows for complementary comparisons to be made regarding antimicrobial exposure in a clinical setting.

Keywords

Antimicrobial consumption, Antimicrobial stewardship, Defined daily dose

Subject

Medicine and Pharmacology, Epidemiology and Infectious Diseases

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.